Developing Covid-19 Vaccines at Pandemic Speed.

By N. Lurie, M. Saville, R. Hatchett, J. Halton. New England Journal of Medicine, 2020

1,354 citations recorded by the source corpus.

Developing Covid-19 Vaccines at Pandemic Speed An ideal vaccine platform would support development from viral sequencing to clinical trials in less than 16 weeks, demonstrate elicitation of consist...

Subfields: Economics and Econometrics, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/71d9d0a132e1d9bb694bd37f1171e9205efc4506

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Wira Winardi
R. Jing
H. Fang
Alex Kurniawan Gan
Haijun Zhang
Jiahao Wang
Hizir Sofyan
Samsul Anwar

Citations in the corpus

Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic (2020, neutral): “Developing COVID-19 vaccines is a crucial challenge, and several candidates are currently under basic development [3].”
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 (2020, neutral): “Prior to our reporting of this BBIBP-CorV study, three candidate vaccines against SARS-CoV-2 were reported, including an adenovirus-vectored vaccine (ChAdOx1 nCoV-19), a DNA vaccine, and an inactivated vaccine (PiCoVacc) (Gao et al., 2020; Lurie et al., 2020; van Doremalen et al., 2020; Yu et al., 2”
Acceptance of a COVID-19 Vaccine in Southeast Asia: A Cross-Sectional Study in Indonesia (2020, background): “Other vaccine candidates, including DNA-based vaccines, inactivated, live attenuated, sub-unit, and replicating viral vectorbased vaccines are also being developed (13).”
Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China (2020, background): “All these findings represented a good start in the process of achieving the coverage rate required to ensure herd immunity among the Chinese population, and the acceleration of COVID-19 vaccine development and listing for application for the public is therefore urged in response to the COVID-19 pand”